LM was much more frequent in NSCLC patients harboring EGFR mutations (9.4%).9 There is no doubt that EGFR‐TKI therapy is the standard first‐line treatment for NSCLC patients with EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.